Abelacimab
Product Specifications
UNSPSC Description
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].
Target Antigen
Factor Xa
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/abelacimab.html
Purity
98.63
Solubility
10 mM in DMSO
Smiles
[Abelacimab]
References & Citations
[1]Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.|[2]Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99415/Abelacimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99415/Abelacimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2098724-83-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Human Monoclonal Carbonic Anhydrase IX/CA9 Antibody (girentuximab-MMAE) [Janelia Fluor 525]](https://cdn.genprice.uk/genprice/genprice3.png)
NBP3-28523JF525 0.1 mL
Human Monoclonal Carbonic Anhydrase IX/CA9 Antibody (girentuximab-MMAE) [Janelia Fluor 525]
Ask
View Details 
